Joanne S
09-18-2007, 09:17 PM
Our members were talking about Neuvenge in 2005:
http://her2support.org/vbulletin/showthread.php?t=19971&highlight=neuvenge
--------------------------------------------------
Following is a current article I found:
Personalized Breast Cancer Vaccine Safe in Early Trial
By Peggy Peck
Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco,
August 22, 2007
For the complete article click URL:
http://www.consultantlive.com/medicalNews/showArticle.jhtml?articleId=201801631 (http://www.consultantlive.com/medicalNews/showArticle.jhtml?articleId=201801631)
Explain to interested patients that this report describes findings from a safety trial of an investigational treatment that is not available for clinical use.
Explain to interested patients that the vaccine being developed targets breast cancers that overexpress HER-2, which would include about 20% to 30% of all breast cancers.
SAN FRANCISCO, Aug. 22 -- A personalized therapeutic breast cancer vaccine was safe and well tolerated when tested in 18 women with metastatic disease overexpressing HER-2, found researchers here.
In the phase 1 trial of the vaccine, lapuleucel-T (APC8024), there were tumor responses in one woman and disease stabilization in three, John W. Park, M.D., of the University of California San Francisco, and colleagues, reported in the Aug. 20 issue of the Journal of Clinical Oncology.
.....
The vaccine is being developed by Dendreon Corporation of Seattle, which is seeking FDA approval of a similar vaccine for prostate cancer. The prostate vaccine, set to be marketed as Provenge, was accepted for FDA fast track review in January after two clinical trials provided evidence that the vaccine stabilized the disease. But the FDA has delayed approval pending evidence that the vaccine can extend survival.
http://her2support.org/vbulletin/showthread.php?t=19971&highlight=neuvenge
--------------------------------------------------
Following is a current article I found:
Personalized Breast Cancer Vaccine Safe in Early Trial
By Peggy Peck
Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco,
August 22, 2007
For the complete article click URL:
http://www.consultantlive.com/medicalNews/showArticle.jhtml?articleId=201801631 (http://www.consultantlive.com/medicalNews/showArticle.jhtml?articleId=201801631)
Explain to interested patients that this report describes findings from a safety trial of an investigational treatment that is not available for clinical use.
Explain to interested patients that the vaccine being developed targets breast cancers that overexpress HER-2, which would include about 20% to 30% of all breast cancers.
SAN FRANCISCO, Aug. 22 -- A personalized therapeutic breast cancer vaccine was safe and well tolerated when tested in 18 women with metastatic disease overexpressing HER-2, found researchers here.
In the phase 1 trial of the vaccine, lapuleucel-T (APC8024), there were tumor responses in one woman and disease stabilization in three, John W. Park, M.D., of the University of California San Francisco, and colleagues, reported in the Aug. 20 issue of the Journal of Clinical Oncology.
.....
The vaccine is being developed by Dendreon Corporation of Seattle, which is seeking FDA approval of a similar vaccine for prostate cancer. The prostate vaccine, set to be marketed as Provenge, was accepted for FDA fast track review in January after two clinical trials provided evidence that the vaccine stabilized the disease. But the FDA has delayed approval pending evidence that the vaccine can extend survival.